CTG Pharma

Enabling Therapeutic Application of Chimeric Antigen Receptor T Cells in Solid Tumors

Health Tech & Life Sciences
Non Active, Sep 2022 ceased to operate

Company Overview

Snapshot

Founded in January 2016 by Yoav Ben-Yaacov, Zelig Eshar, and Salomon Stemmer, CTG Pharma operated with 1–10 employees. The company raised $2 million across one funding round from aMoon Fund. In September 2018, CTG Pharma secured seed funding.

Business overview

CTG Pharma developed solutions for chimeric antigen receptor (CAR) T cell therapy, specifically targeting HER2-positive solid tumors while aiming to mitigate toxicity and on-target off-tumor reactions. The company's technology includes a library of 65,000 promoters designed to enable safer CAR T applications for solid tumors, adaptable to various CAR types and tumor microenvironments. CTG Pharma aimed to establish a broadly applicable platform to enhance the safety and efficacy of human CAR T therapies requiring regulated CAR expression, with an initial focus on HER2-positive cancers. The company operated within the Health Tech & Life Sciences sector, focusing on pharmaceuticals and oncology.

Company Intelligence Q&A

What is CTG Pharma's primary focus?
CTG Pharma focuses on developing solutions to enable chimeric antigen receptor (CAR) T cell therapy for HER2-positive solid tumors, aiming to reduce toxicity and off-target effects.
When was CTG Pharma founded?
CTG Pharma was founded in January 2016.
Who are the co-founders of CTG Pharma?
CTG Pharma was co-founded by Yoav Ben-Yaacov, Zelig Eshar, and Salomon Stemmer.
What was CTG Pharma's last known funding event?
In September 2018, CTG Pharma secured $2 million in seed funding from aMoon Fund.
What is the current operational status of CTG Pharma?
CTG Pharma is non-active and ceased to operate in September 2022.

External links